PRA Health Sciences Inc (NASDAQ:PRAH) Expected to Post Quarterly Sales of $794.10 Million

Share on StockTwits

Analysts predict that PRA Health Sciences Inc (NASDAQ:PRAH) will post $794.10 million in sales for the current quarter, Zacks reports. Five analysts have issued estimates for PRA Health Sciences’ earnings. The lowest sales estimate is $790.37 million and the highest is $800.30 million. PRA Health Sciences reported sales of $729.65 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.8%. The business is scheduled to issue its next earnings report after the market closes on Thursday, February 20th.

According to Zacks, analysts expect that PRA Health Sciences will report full-year sales of $3.06 billion for the current fiscal year, with estimates ranging from $3.06 billion to $3.07 billion. For the next fiscal year, analysts expect that the company will report sales of $3.30 billion, with estimates ranging from $3.28 billion to $3.34 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow PRA Health Sciences.

A number of equities analysts have commented on PRAH shares. Zacks Investment Research lowered shares of PRA Health Sciences from a “hold” rating to a “sell” rating and set a $116.00 price objective on the stock. in a report on Tuesday, December 31st. Citigroup started coverage on shares of PRA Health Sciences in a report on Monday, January 6th. They issued a “neutral” rating and a $120.00 price objective on the stock. Goldman Sachs Group lowered shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $130.00 to $120.00 in a report on Friday, January 10th. BidaskClub lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, January 11th. Finally, Wolfe Research upgraded shares of PRA Health Sciences from a “peer perform” rating to an “outperform” rating and set a $123.00 price objective on the stock in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $116.40.

Shares of PRA Health Sciences stock opened at $111.22 on Friday. The company has a fifty day moving average price of $106.56 and a 200 day moving average price of $102.74. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 1.65. PRA Health Sciences has a twelve month low of $85.00 and a twelve month high of $115.50. The stock has a market cap of $6.97 billion, a price-to-earnings ratio of 30.89, a price-to-earnings-growth ratio of 1.44 and a beta of 1.21.

Hedge funds have recently modified their holdings of the business. Caxton Associates LP acquired a new stake in PRA Health Sciences during the fourth quarter worth about $214,000. Captrust Financial Advisors acquired a new stake in PRA Health Sciences during the fourth quarter worth about $18,731,000. Cubist Systematic Strategies LLC raised its stake in PRA Health Sciences by 185.4% during the fourth quarter. Cubist Systematic Strategies LLC now owns 48,456 shares of the medical research company’s stock worth $5,386,000 after acquiring an additional 31,480 shares during the period. Bank of America Corp DE raised its stake in PRA Health Sciences by 10.0% during the fourth quarter. Bank of America Corp DE now owns 197,941 shares of the medical research company’s stock worth $22,000,000 after acquiring an additional 18,002 shares during the period. Finally, Ellington Management Group LLC acquired a new stake in PRA Health Sciences during the fourth quarter worth about $245,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: What is the Gross Domestic Product (GDP)?

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Anticipate Cango Inc –  Will Post Earnings of $0.09 Per Share
Brokerages Anticipate Cango Inc – Will Post Earnings of $0.09 Per Share
Logitech International  Downgraded by BidaskClub to Strong Sell
Logitech International Downgraded by BidaskClub to Strong Sell
Bunzl’s  Neutral Rating Reaffirmed at UBS Group
Bunzl’s Neutral Rating Reaffirmed at UBS Group
Meggitt’s  Sell Rating Reaffirmed at UBS Group
Meggitt’s Sell Rating Reaffirmed at UBS Group
Avast  Rating Reiterated by UBS Group
Avast Rating Reiterated by UBS Group
Motorcar Parts of America  Upgraded to “Hold” by BidaskClub
Motorcar Parts of America Upgraded to “Hold” by BidaskClub


 
© 2006-2020 Zolmax.